Editorial & Opinion
أعرض في EDS

Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data.

التفاصيل البيبلوغرافية
العنوان: Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data.
المؤلفون: Calip GS; Flatiron Health, New York, New York.; Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, Illinois., Wadé NB; Flatiron Health, New York, New York.; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California., Guadamuz JS; Flatiron Health, New York, New York.; Program on Medicines and Public Health, School of Pharmacy, University of Southern California, Los Angeles, California., Wang X; Flatiron Health, New York, New York., Miksad RA; Flatiron Health, New York, New York.; Department of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts., Whitaker KD; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
المصدر: Cancer [Cancer] 2022 Feb 15; Vol. 128 (4), pp. 647-650. Date of Electronic Publication: 2021 Dec 07.
نوع المنشور: Editorial; Comment
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
مواضيع طبية MeSH: Breast Neoplasms*/mortality , Breast Neoplasms*/therapy , Cardiovascular Diseases*/epidemiology, Black or African American ; Female ; Healthcare Disparities ; Humans
التعليقات: Comment on: Cancer. 2022 Feb 15;128(4):727-736. (PMID: 34873682)
References: Brawley OW, Berger MZ. Cancer and disparities in health: perspectives on health statistics and research questions. Cancer. 2008;113:1744-1754.
Hunt BR, Whitman S, Hurlbert MS. Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol. 2014;38:118-123.
Ko NY, Hong S, Winn RA, Calip GS. Association of insurance status and racial disparities with the detection of early-stage breast cancer. JAMA Oncol. 2020;6:385-392.
Yedjou CG, Tchounwou PB, Payton M, et al. Assessing the racial and ethnic disparities in breast cancer mortality in the United States. Int J Environ Res Public Health. 2017;14:486.
Daly B, Olopade OI. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015;65:221-238.
Reeder-Hayes KE, Anderson BO. Breast cancer disparities at home and abroad: a review of the challenges and opportunities for system-level change. Clin Cancer Res. 2017;23:2655-2664.
Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013;20:1301-1309.
Lau ES, Paniagua SM, Liu E, et al. Cardiovascular risk factors are associated with future cancer. JACC CardioOncol. 2021;3:48-58.
Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137:e30-e66.
Livi L, Barletta G, Martella F, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol. 2021;7:1544-1549.
Fazal M, Malisa J, Rhee JW, Witteles RM, Rodriguez F. Racial and ethnic disparities in cardio-oncology: a call to action. JACC CardioOncol. 2021;3:201-204.
Connor AE, Kaur M, Sheng JY, Hayes JH. Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: impact of cardiovascular disease and clinical characteristics. Cancer. 2022;128.
Hassett MJ, Schymura MJ, Chen K, Boscoe FP, Gesten FC, Schrag D. Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer. 2016;122:420-431.
Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117:180-189.
Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2011;7:371-374.
Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care. 2010;48:S96-S105.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316:1818-1819.
Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013;105:1456-1462.
Tarantino P, Tolaney SM, Harbeck N, Cortes J, Curigliano G. Anthracyclines for human epidermal growth factor receptor 2-positive breast cancer: are we ready to let them go? J Clin Oncol. 2021;39:3541-3545.
Battisti NML, Andres MS, Lee KA, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat. 2021;188:149-163.
Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945-1960.
Branch M, Malaver D, Vasu S. Racial differences in incidence of cardiotoxicity in breast cancer patients: a real world study. J Am Coll Cardiol. 2020;75:841.
Litvak A, Batukbhai B, Russell SD, et al. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer. 2018;124:1904-1911.
فهرسة مساهمة: Keywords: breast cancer; cardiovascular disease; competing risks; racial disparities; real-world data
تواريخ الأحداث: Date Created: 20211207 Date Completed: 20220309 Latest Revision: 20221207
رمز التحديث: 20221213
DOI: 10.1002/cncr.34045
PMID: 34873685
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0142
DOI:10.1002/cncr.34045